Quanterix Corp (NASDAQ:QTRX) Director Sells $40,400.00 in Stock

Quanterix Corp (NASDAQ:QTRX) Director Martin D. Madaus sold 1,600 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $25.25, for a total value of $40,400.00. Following the completion of the sale, the director now owns 8,149 shares in the company, valued at approximately $205,762.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of Quanterix stock traded up $0.05 during midday trading on Friday, hitting $24.96. The company had a trading volume of 707 shares, compared to its average volume of 99,419. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.00 and a current ratio of 7.61. The stock has a market capitalization of $704.29 million, a P/E ratio of -17.46 and a beta of 1.36. The company has a 50 day moving average of $23.27 and a 200 day moving average of $26.37. Quanterix Corp has a 52-week low of $17.08 and a 52-week high of $36.15.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.01. The company had revenue of $14.94 million for the quarter, compared to the consensus estimate of $12.52 million. Quanterix had a negative return on equity of 54.74% and a negative net margin of 75.78%. Equities research analysts forecast that Quanterix Corp will post -1.52 EPS for the current year.

Several institutional investors have recently bought and sold shares of QTRX. Ashford Capital Management Inc. purchased a new stake in shares of Quanterix in the 2nd quarter worth approximately $13,333,000. Gilder Gagnon Howe & Co. LLC boosted its stake in Quanterix by 11.6% during the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 3,422,605 shares of the company’s stock valued at $75,160,000 after purchasing an additional 354,437 shares during the last quarter. BlackRock Inc. boosted its stake in Quanterix by 29.7% during the 2nd quarter. BlackRock Inc. now owns 877,059 shares of the company’s stock valued at $29,636,000 after purchasing an additional 200,999 shares during the last quarter. Kornitzer Capital Management Inc. KS purchased a new stake in Quanterix during the 3rd quarter valued at $3,604,000. Finally, Tikvah Management LLC boosted its stake in Quanterix by 125.0% during the 2nd quarter. Tikvah Management LLC now owns 238,489 shares of the company’s stock valued at $8,059,000 after purchasing an additional 132,500 shares during the last quarter. Institutional investors own 67.50% of the company’s stock.

Several research firms recently weighed in on QTRX. Canaccord Genuity restated a “buy” rating and issued a $35.00 price target on shares of Quanterix in a research note on Thursday, November 7th. Zacks Investment Research upgraded Quanterix from a “sell” rating to a “hold” rating in a research note on Tuesday, November 26th.

About Quanterix

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.

See Also: What does a bar chart mean for investors?

Insider Buying and Selling by Quarter for Quanterix (NASDAQ:QTRX)

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.